Email this article Drug treatment for cancer of the corpus uteri: Protracted stagnation or breakthrough expectation
- Authors: Artamonova E.V.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: No 3 (2011)
- Pages: 83-87
- Section: GYNECOLOGY. TREATMENT
- Published: 14.08.2011
- URL: https://ojrs.abvpress.ru/ojrs/article/view/183
- DOI: https://doi.org/10.17650/1994-4098-2011-0-3-83-87
- ID: 183
Cite item
Full Text
Abstract
The paper considers the specific features of the course and therapy of cancer of the corpus uteri on the basis of some clinical and biological characteristics of the tumor. The objective of ongoing and future clinical trials is to expand the arsenal of active drugs and to individualize therapy in patients with endometrial cancer.
Keywords
About the authors
E. V. Artamonova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: artamonovae@mail.ru
Russian Federation
References
Supplementary files
